Incyte Corp (INCY)

117.22
0.31 0.26
NASDAQ : Health Care
Prev Close 117.53
Open 118.32
Day Low/High 117.08 / 122.68
52 Wk Low/High 55.00 / 133.62
Volume 1.91M
Avg Volume 1.42M
Exchange NASDAQ
Shares Outstanding 188.39M
Market Cap 21.41B
P/E Ratio 145.68
Div & Yield N.A. (N.A)

Latest News

Merck Cancer Drug Test Sends Incyte Shares Higher

Merck Cancer Drug Test Sends Incyte Shares Higher

The companies will study epacadostat in tandem with Merck's Keytruda in patients with non-small cell lung, renal, bladder and head and neck cancers.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.

Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)

Incyte And Merck To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of...

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease

Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids for the treatment of...

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 35 th Annual J.

Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)

Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)

Incyte Corporation (Nasdaq:INCY) today announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall...

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Get Excited About Incyte

Get Excited About Incyte

Prices have marched their way all the way back up to the bottom end of key resistance.

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Stericycle

The most recent short interest data has been released for the 10/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi ® (ruxolitinib) and its small molecule development programs targeting...

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 11:30 am (EST) in New York.

Incyte Reports 2016 Third-Quarter Financial Results And Updates Key Clinical Programs

Incyte Reports 2016 Third-Quarter Financial Results And Updates Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2016 third-quarter financial results, including strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

There's Still Time to Buy These 5 Breakout Trades

There's Still Time to Buy These 5 Breakout Trades

November is historically a great month for stock market performance -- here's how you can stack the deck in your favor.

Incyte To Report Third Quarter Financial Results

Incyte To Report Third Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2016 financial results conference call and webcast for 10:00 a.

Additional Phase 1 Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda® (pembrolizumab)

Additional Phase 1 Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) today announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination...

Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab)

Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab)

Incyte Corporation (Nasdaq: INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating...

The New #42 Most Shorted Nasdaq 100 Component: Incyte

The New #42 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis

NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis

Incyte Corporation (Nasdaq: INCY) today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi ® (ruxolitinib), has been included as a recommended treatment in the latest National Comprehensive Cancer...

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Incyte Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month

Incyte Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month

Incyte Corporation calls for increased awareness and support for those living with myeloproliferative neoplasms (MPNs) today, MPN Awareness Day, and throughout September, Blood Cancer Awareness Month.